Literature DB >> 16891200

Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis.

Hongyu Ni1, Giovanni Barosi, Ronald Hoffman.   

Abstract

Bone marrow angiogenesis in patients with idiopathic myelofibrosis (IM) was evaluated by using a quantitative morphometric analysis test system. IM specimens had a significantly higher degree of bone marrow microvessel density (MVD) compared with control specimens. The higher degree of angiogenesis was associated with increased expression of basic fibroblast growth factor in megakaryocytes and endothelial cells in the IM bone marrow specimens. Increased vascular endothelial growth factor expression was seen in some cases of the prefibrotic form of IM. Morphometric quantitative measurements revealed that the MVD was reduced progressively in 4 cases of IM after allogeneic stem cell transplantation. These findings suggest that angiogenesis likely has an important role in the pathogenesis of IM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891200     DOI: 10.1309/4YGK-ED5L-WFW4-AVDV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

Review 1.  Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?

Authors:  R Tamari; T I Mughal; D Rondelli; R Hasserjian; V Gupta; O Odenike; V Fauble; G Finazzi; F Pane; J Mascarenhas; J Prchal; S Giralt; R Hoffman
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Phase I/II study of single-agent bortezomib for the treatment of patients with myelofibrosis. Clinical and biological effects of proteasome inhibition.

Authors:  Giovanni Barosi; Elisabetta Gattoni; Paola Guglielmelli; Rita Campanelli; Fabio Facchetti; Simona Fisogni; Judith Goldberg; Roberto Marchioli; Ronald Hoffman; Alessandro M Vannucchi
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

Review 3.  Rational therapeutic options for patients with myeloproliferative neoplasms.

Authors:  Ronald Hoffman
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

4.  Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells.

Authors:  Min Lu; Lijuan Xia; Yen-Chun Liu; Tsivia Hochman; Laetizia Bizzari; Daniel Aruch; Jane Lew; Rona Weinberg; Judith D Goldberg; Ronald Hoffman
Journal:  Blood       Date:  2015-05-28       Impact factor: 22.113

5.  Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Authors:  Stefan O Ciurea; Delwin Merchant; Nadim Mahmud; Takefumi Ishii; Yan Zhao; Wenyang Hu; Edward Bruno; Giovanni Barosi; Mingjiang Xu; Ronald Hoffman
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

6.  Genes Involved in Maintaining the Bone Marrow Stroma Are Dysregulated in Patients with Myelofibrosis: Lenalidomide Treatment Up-regulates SOCS3.

Authors:  Ana Livun; Kate J Newberry; Taghi Manshouri; Rajko Kusec; Srdan Verstovsek
Journal:  Anticancer Res       Date:  2015-10       Impact factor: 2.480

Review 7.  Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Nadira Ruzehaji; Marie-Caroline Le Bousse-Kerdilès
Journal:  Mediators Inflamm       Date:  2015-11-12       Impact factor: 4.711

8.  Does angiogenesis matter in primary myelofibrosis?

Authors:  Paulo Vidal Campregher
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-17

9.  Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor.

Authors:  Cesar Cilento Ponce; Maria de Lourdes Lopes Ferrari Chauffaille; Silvia Saiuli Miki Ihara; Maria Regina Regis Silva
Journal:  Rev Bras Hematol Hemoter       Date:  2014-07-18

Review 10.  Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Authors:  Gregor Hoermann; Georg Greiner; Peter Valent
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.